Bristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it be about repeat the trick with a new drug that stimulates natural kill
Creating cancer therapies based around natural killer cells could offer similar levels of efficacy to CAR-T therapies, but at around one hundredth of the cost.
Johnson & Johnson is rolling out its ‘no strings attached’ innovation incubator project JLABS to Europe – and has chosen a site in Belgium with a link to the company’s history.
